CDK1 and leiomyoma: Although no previous studies have analyzed CDK1 overexpression in leiomyosarcomas versus leiomyomas through immunohistochemistry, CDK1 has been proposed as a potential diagnostic biomarker for rhabdomyosarcoma [49].